Back to mobile site

Morgan Stanley Upgrades Ascendis Pharma (ASND) to Overweight

May 5, 2025 3:29 AM EDT Send to a Friend
Morgan Stanley analyst Vikram Purohit upgraded Ascendis Pharma (NASDAQ: ASND) from Equalweight to Overweight with a price target of $250.00 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login